Inogen Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Kevin R. Smith

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage	4.4%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	2.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin R. Smith's remuneration changed compared to Inogen's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$2m	US$108k	-US$102m

Compensation vs Market: Kevin R.'s total compensation ($USD2.45M) is above average for companies of similar size in the German market ($USD691.02K).

Compensation vs Earnings: Insufficient data to compare Kevin R.'s compensation with company performance.

CEO

Kevin R. Smith (52 yo)

less than a year

Tenure

US$2,448,754

Compensation

Mr. Kevin R. M. Smith serves as President, CEO and Director at Inogen Inc. since November 13, 2023. He served as Director at OncoSec Medical Incorporated since February 7, 2020 until June 14, 2023 and serv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin R. Smith	President	less than a year	US$2.45m	no data
Jason Somer	Executive VP	2.8yrs	US$841.01k	0.028% $ 41.0k
Stanislav Glezer	Executive VP of R&D and Chief Medical Officer	less than a year	US$1.46m	0.068% $ 101.9k
Michael Bourque	Executive VP	less than a year	no data	no data
Philip Corrin	Senior Vice President of Operations & Supply Chain	1.2yrs	no data	no data
Jennifer Boyer	Executive VP & Chief Human Resources Officer	1.9yrs	no data	no data
Vijay Paliwal	Senior Vice President of Enterprise Enablement	1.7yrs	no data	no data
Grgoire Ramade	Executive VP & Chief Commercial Officer	less than a year	no data	no data

0.8yrs

Average Tenure

53yo

Average Age

Experienced Management: 6IO's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin R. Smith	President	less than a year	US$2.45m	no data
Richard Casaburi	Member of Advisory Board	no data	no data	no data
Jeffrey Kupperman	Member of Advisory Board	no data	no data	no data
Paul Selecky	Member of Advisory Board	no data	no data	no data
Mary Ladone	Independent Director	2.1yrs	US$242.50k	0.031% $ 46.2k
Kevin King	Independent Director	2.1yrs	US$250.00k	0.031% $ 46.2k
Neil MacIntyre	Member of Advisory Board	no data	no data	no data
Elizabeth Mora	Independent Board Chairperson	2.9yrs	US$315.00k	0.041% $ 60.7k
Robert Chatburn	Member of Advisory Board	no data	no data	no data
Thomas West	Independent Director	less than a year	US$266.24k	0.0073% $ 10.8k
Heather Rider	Independent Director	9.7yrs	US$242.50k	0.088% $ 130.5k
Glenn Boehnlein	Independent Director	2.1yrs	US$250.00k	0.031% $ 46.2k

2.1yrs

Average Tenure

61yo

Average Age

Experienced Board: 6IO's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Inogen Management

Management criteria checks 0/4

Key information

Recent management updates

Inogen, Inc., Annual General Meeting, Jun 05, 2024

Inogen, Inc. Announces CFO Changes, Effective March 4, 2024

Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen Announces CEO Changes

Recent updates

New minor risk - Shareholder dilution

Inogen, Inc., Annual General Meeting, Jun 05, 2024

Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024

Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024

Full year 2023 earnings released: US$4.42 loss per share (vs US$3.67 loss in FY 2022)

Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Inogen, Inc. Announces CFO Changes, Effective March 4, 2024

Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen Announces CEO Changes

Third quarter 2023 earnings released: US$1.97 loss per share (vs US$0.41 loss in 3Q 2022)

New minor risk - Market cap size

Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Inogen, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 loss in 2Q 2022)

Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United States

Inogen, Inc. Announces Board Changes

Inogen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Inogen, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.88 loss per share (vs US$0.63 loss in 1Q 2022)

Full year 2022 earnings released: US$3.67 loss per share (vs US$0.28 loss in FY 2021)

Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023

Inogen, Inc. to Report Q4, 2022 Results on Feb 23, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.54 profit in 3Q 2021)

Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.23 profit in 2Q 2021)

High number of new and inexperienced directors

Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive Index

Inogen, Inc. Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, Effective May 23, 2022

Inogen, Inc. Provides Earnings Guidance for the Second Quarter of 2022

High number of new and inexperienced directors

Inogen, Inc., Annual General Meeting, Jun 08, 2022

Inogen, Inc. Announces Management Changes

Inogen, Inc. to Report Q1, 2022 Results on May 05, 2022

High number of new and inexperienced directors

Inogen, Inc. Executive Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Loren McFarland Not to Stand for Re-Election as Director of Inogen, Inc

Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021

Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.077 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.23 (vs US$0.12 in 2Q 2020)

Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 3000E Value Index

Inogen, Inc. Unable to Provide Guidance for the Full Year 2021

Inogen Announces Board Changes

Inogen, Inc. Unables to Provide Guidance for the Full Year 2021

Inogen, Inc Announces Management Changes

Independent Director has left the company

Inogen, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €42.00

Inogen, Inc. Announces Change of Chief Executive Officers

Inogen, Inc. Announces Board Changes

Inogen, Inc. Unable to Provide Guidance for the Full Year 2020 or 2021

Inogen, Inc. to Report Q3, 2020 Results on Nov 04, 2020

New 90-day low - €22.80

New 90-day low - €24.80

First half earnings released

Inogen, Inc. to Report Q2, 2020 Results on Aug 04, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members